Imagine the money that could be made by a drug company that accurately predicted and treated the onset of Alzheimer’s before any symptoms surfaced. That may give us an idea why NeuroVigil, a company specializing in non-invasive, wireless brain-recording tech, just got a cash injection that puts it at a valuation “twice the combined seed valuations of Google’s and Facebook’s first rounds,” according to a company announcement.

Facebook‘s Series A funding in May 2005 was at $12.7 million, valuing the firm at $98 million. Some figure put the series Series A funding of Google, on a $25 million co-investment from Sequoia and Kleiner Perkins, at $75 million in late 1999. Add those valuations. Double ’em, and it would seem NeuroVigil got tens of millions in early cash, enough for a valuation of roughly $250 million.

Most of it came from one moneybags, an “anonymous American industrialist and technology visionary,” NeuroVigil says. There were other participants dotted across the U.S. Bill Gates, who’s loaded and philanthropic, and Steve Jobs, who’s loaded and focused on health (his own, especially), may have an interest in investing in clever medical technology.

NeuroVigil describes itself as a neurotechnology company centered on a “fundamentally new way to assess brain activity, non-invasively, and rapidly, using a single channel of electroencephalogram.”

NeuroVigil’s key product at the moment is the iBrain, a slim device in a flexible head-cap that’s designed to be worn for continuous EEG monitoring of a patient’s brain function–mainly during sleep. It’s non-invasive, and replaces older technology that could only access these kind of brain functions via critically implanted electrodes actually on the brain itself. The idea is, first, to record how brain function changes over time, perhaps as a particular combination of drugs is administered or to help diagnose particular brain pathologies–such as epilepsy.

iBrain promises to open a huge pipeline of data with its powerful but simple brain-reading tech, which is gaining traction thanks to technological advances. But the other half of the potentailly lucrative equation is the ability to analyze the trove of data coming from iBrain. And that’s where NeuroVigil’s SPEARS algorithm enters the picture. Not only is the company simplifying collection of brain data with a device that can be relatively comfortably worn during all sorts of tasks–sleeping, driving, watching advertising–but the combination of iBrain and SPEARS multiplies the efficiency of data analysis. Here’s NeuroVigil on that: